Teva’s $420mn investor settlement to be mostly covered by insurers

Teva has agreed a $420mn settlement of shareholder litigation over an alleged anti-competitive scheme to fix generic drug pricing, with a spokesperson for the pharmaceutical company telling Reuters the “vast majority” will be covered by insurers.